Medtronic Stock News

Pune, India, Feb. 09, 2022 (GLOBE NEWSWIRE) -- The Bone Void Fillers Market to Generate USD 3.90 Billion by 2027 Owing to Increasing Prevalence of Bone-Associated Disease, with stunning 5.4% CAGR by 2021-2027. Adoption of Technologically Advanced Products Globally to Surge Demand. Biocomposites Receiving CE Mark from The European Union to Create Exponential Growth Opportunities Industry Development: In September 2018, US-based Baxter International Inc. obtained clearance from U.S. Food and Drug Administration or FDA for ALTAPORE Bioactive Bone Graft. This medical invention is a next generation osteoconductive and bioactive substitute of bone grafts. In 2019, Medtronic plc introduced Grafton demineralized bone matrix (DBM) bone grafting product to the Japanese market. Grafton DBM is the first of its kind demineralized bone matrix product that is made available in Japan. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bone-void-fillers-market-101015 Scope Of The Report: Historical Years: 2016-2018 Base Year: 2019 Forecast Period: 2020–2027 Drivers and Restraints: Rising demand, coupled with increased awareness about advanced technology enabled orthopedic surgeries in India and China in the recent years, is expected to boost the demand for bone void fillers.

DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2022 on Tuesday, February 22, 2022. A news release will be issued at approximately 5:45 a.m.

DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2022

Medtronic (MDT) closed at $101.99 in the latest trading session, marking a -0.72% move from the prior day.

Medtronic Plc (NYSE: MDT ) has initiated a voluntary recall to customers related to the risk associated with tip damage caused by guidewire prolapse in its 6 French (6Fr) TurboHawk Plus Directional Atherectomy System. Recently, Medtronic issued a recall for the HawkOne Atherectomy system due to tip damage risk , Full story available on Benzinga.com

Pune, India, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The global pulse oximeters market is likely to grow in the coming years due to increasing usage clearances from the Food and Drug Administration (FDA). According to a report published by Fortune Business Insights, titled "Pulse Oximeters: Global Market Analysis, Insights and Forecast, 2018-2025," the market is likely to reach US$ 2,657.6 Mn by the end of 2025. Fortune Business Insights states that the market was valued at US$ 1,587.3 Mn in 2017 and will exhibit a CAGR of 6.7% in the forecast period. In the report, Fortune Business Insights has profiled a few companies that are operating in the global pulse oximeter market. Some of the leading companies that have been identified as significant growth contributors are GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V, Masimo, Messe Düsseldorf GmbH, VYAIRE, Opto Circuits (India) Limited, Medtronic, Omron Healthcare, Inc., Nonin, and B Smiths Group plc. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/pulse-oximeters-market-100528 Masimo''s Approval for Radius PPG to Trigger Growth In 2019, Masimo received clearance for its latest pulse oximeter.

Zimmer (ZBH) delivered earnings and revenue surprises of -0.51% and 0.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.

Medtronic Plc (NYSE: MDT) has initiated a voluntary recall to customers related to the risk associated with tip damage caused by guidewire prolapse in its 6 French (6Fr) TurboHawk Plus Directional At

Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.

COVID-19 has slowed down growth, but long-term prospects look very promising.

The opposite of the old adage to "buy the rumor, sell the news" doesn't apply to ShockWave.

New government program enables access to integrated hybrid closed loop technology for 18 and under BRAMPTON, ON , Feb. 3, 2022 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, applauds the Alberta government''s announcement of a comprehensive reimbursement program for continuous glucose monitoring (CGM) for eligible residents living with diabetes, under the age of 18. CGM devices provide critical information on glucose levels to help with the management of diabetes. Medtronic fully supports this investment in the health of young people living with diabetes, enabling access to innovative diabetes management technology to help improve control of this very challenging chronic disease. "Before I had CGM, it was all about worrying whether I could get through my day and keep my numbers in range," shares Savannah Seibel , a 17 year-old high school student and viola player from Edmonton, Alberta . "It was always there in the back of my mind.

Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.